Local nasal immunotherapy: efficacy of low-dose aqueous ragweed extract.
In previous studies preseasonal local nasal immunotherapy (LNIT) with moderate doses of aqueous ragweed extract (mean total dose 59 micrograms of AgE and 139 micrograms of AgE) was an effective treatment for ragweed hay fever; however, local adverse reactions during therapy were common. This study evaluated the clinical and immunologic responses to LNIT by use of lower doses of aqueous ragweed extract in order to minimize these adverse reactions. Patients were administered preseasonal LNIT for 7 wk and received a mean total dose of 4.7 micrograms of AgE. During the ragweed season, symptom/medication scores (SMS) of the treated patients were equivalent to SMS of untreated patients. Serum ragweed-specific IgE and nasal secretory ragweed-specific IgA rose slightly in the treated patients but not to the extent observed in previous studies. After the ragweed season treated and untreated patients had a substantial increase in serum ragweed IgE antibody titers. No correlation could be found between antibody responses and SMS. This study indicates that LNIT with lower doses of aqueous ragweed extract is clinically ineffective.
D000281:Administration, Intranasal; D000485:Allergens; D052179:Antigens, Plant; D006801:Humans; D007071:Immunoglobulin A, Secretory / Q000032:analysis; D007167:Immunotherapy / Q000009:adverse effects / Q000592:standards*; D009297:Nasal Mucosa / Q000276:immunology / Q000378:metabolism; D008517:Phytotherapy; D010936:Plant Extracts / Q000008:administration & dosage*; D010940:Plant Proteins; D011058:Pollen / Q000008:administration & dosage
D000485:Allergens; C026967:Amb a I protein, Ambrosia artemisiifolia; D052179:Antigens, Plant; D007071:Immunoglobulin A, Secretory; D010936:Plant Extracts; D010940:Plant Proteins